Cargando…

S109: P53 ORCHESTRATES SPATIO-TEMPORAL EPIGENOME REWIRING TO TRANSCRIPTIONALLY PREVENT MALIGNANT TRANSFORMATION

Detalles Bibliográficos
Autores principales:	Serra, François, Cabrera, Monica, Rovirosa, Llorenc, Nieto-Aliseda, Andrea, Fnalo-Escudero, Lucía, Valencia, Alfonso, Javierre, Biola M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428347/ http://dx.doi.org/10.1097/01.HS9.0000967348.67884.fc

Ejemplares similares

The Genome in a Three-Dimensional Context: Deciphering the Contribution of Noncoding Mutations at Enhancers to Blood Cancer
por: Rovirosa, Llorenç, et al.
Publicado: (2020)

Low input capture Hi-C (liCHi-C) identifies promoter-enhancer interactions at high-resolution
por: Tomás-Daza, Laureano, et al.
Publicado: (2023)

S108: ATP CITRATE LYASE IS AN ESSENTIAL PLAYER OF THE METABOLIC REWIRING INDUCED BY PTEN LOSS DURING T-ALL DEVELOPMENT
por: Andrieu, Guillaume, et al.
Publicado: (2023)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Integrating epigenomic data and 3D genomic structure with a new measure of chromatin assortativity
por: Pancaldi, Vera, et al.
Publicado: (2016)

S175: SINGLE-CELL ANALYSIS REVEALS SOMATIC TP53 MUTATIONS EMERGE IN EARLY PROGENITOR CELLS BUT BECOME ENRICHED IN THE ERYTHROID LINEAGE IN ERCC6L2 DISEASE
por: Langohr, Laura, et al.
Publicado: (2023)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

M109. WEIGHT GAIN AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
Publicado: (2020)

Infections inhabituelles
Publicado: (2011)

Grippe A (H1N1) en réanimation
Publicado: (2010)

ECMO veinoveineuse
Publicado: (2013)

Bookmarking the epigenome by retrovirus integration
por: Senigl, Filip, et al.
Publicado: (2011)

S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2023)

T109. TRAVERSING THE TRANSDIAGNOSTIC GAP BETWEEN DEPRESSION, MANIA AND PSYCHOSIS WITH NATURAL LANGUAGE PROCESSING
por: Patel, Rashmi, et al.
Publicado: (2020)

WS20.02 Input supporting a young person with increased cough suppression in the context of COVID-19
por: Shayle, A., et al.
Publicado: (2022)

WS05.04 SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells
por: Lotti, V., et al.
Publicado: (2022)

WS21.03 Low-cost chain termination DNA sequencing PCR reaction to diagnose CFTR gene mutations
por: Ghani, M.U., et al.
Publicado: (2022)

WS20.06 Co-infection with Nocardia farcinia and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis
por: Chapman, J., et al.
Publicado: (2022)

WS21.01 AQP5 and CFTR, two genes associated with pseudo-aquagenic palmoplantar keratoderma?
por: Girodon, E., et al.
Publicado: (2022)

S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA
por: Châtel-Soulet, Hugues-Etienne, et al.
Publicado: (2022)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
por: Sun, K., et al.
Publicado: (2022)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES
por: Meyer, E., et al.
Publicado: (2022)

S234: CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION
por: Shang, Q.-N., et al.
Publicado: (2022)

S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
por: Riedel, Anna, et al.
Publicado: (2023)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
por: Ayala, Rosa, et al.
Publicado: (2023)

S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

S250: UNVEILING THE BIOLOGICAL ROLE OF PERIPHERAL BLOOD HUMAN CIRCULATING HEMATOPOIETIC STEM AND PROGENITOR CELLS
por: Quaranta, Pamela, et al.
Publicado: (2023)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME
por: Hanna, Rabi, et al.
Publicado: (2023)

S185: TARGETING DNA2 OVERCOMES METABOLIC REPROGRAMMING IN 1Q21 MULTIPLE MYELOMA
por: Thongon, Natthakan, et al.
Publicado: (2023)

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Jacobson, Caron, et al.
Publicado: (2023)

S259: SAR444245, A NON-ALPHA IL2, RESCUES CHRONIC ANTIGEN- AND CAR-DRIVEN T-CELL DYSFUNCTION
por: Sheikh, Irtiza, et al.
Publicado: (2023)

S298: MATERNAL AND FETAL OUTCOMES IN PREGNANCIES OF WOMEN WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER RETROSPECTIVE OBSERVATIONAL ITP-NET ITALIAN STUDY
por: Carpenedo, Monica, et al.
Publicado: (2023)

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS
por: Bruins, Wassilis, et al.
Publicado: (2023)

S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
por: Kenet, Gili, et al.
Publicado: (2023)

S221: LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)
por: Ladetto, Marco, et al.
Publicado: (2023)

S289: PPP1R1B BINDS IRON REGULATORY PROTEINS AND MODULATES IRON CELLULAR CONTENT
por: Calvo López, Laura, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_99q2v5eo12ffosoh7sektesv6s